Work

Metabolic Subtyping for Novel Personalized Therapies Against Pancreatic Cancer

Year: 2019

Type: article

Abstract: Through metabolic subtyping, metabolic vulnerabilities can be exploited for developing efficacious treatments. A glycolytic subtype indicates poor survival in patients with pancreatic cancer, whereas a cholesterogenic subtype correlates with better outcomes potentially due to more energy expenditure. Personalized medicine holds great promise for improving therapy outcomes by optimally targeting metabolic pathways. See related article by Karasinska et al., p. 135

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-19-2926

Authors: Kamiya Mehla, Pankaj K. Singh

Institution: University of Nebraska Medical Center

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: National Institutes of Health, National Cancer Institute